RedHill Biopharma (RDHL) Return on Assets (2016 - 2024)
Historic Return on Assets for RedHill Biopharma (RDHL) over the last 12 years, with Q4 2024 value amounting to 2.94%.
- RedHill Biopharma's Return on Assets rose 35800.0% to 2.94% in Q4 2024 from the same period last year, while for Dec 2024 it was 2.94%, marking a year-over-year increase of 35800.0%. This contributed to the annual value of 711267.64% for FY2024, which is 7112679000.0% down from last year.
- According to the latest figures from Q4 2024, RedHill Biopharma's Return on Assets is 2.94%, which was up 35800.0% from 2.26% recorded in Q2 2024.
- Over the past 5 years, RedHill Biopharma's Return on Assets peaked at 2.94% during Q4 2024, and registered a low of 0.91% during Q3 2022.
- For the 5-year period, RedHill Biopharma's Return on Assets averaged around 0.11%, with its median value being 0.24% (2021).
- Per our database at Business Quant, RedHill Biopharma's Return on Assets tumbled by -12300bps in 2022 and then skyrocketed by 35800bps in 2024.
- Quarter analysis of 5 years shows RedHill Biopharma's Return on Assets stood at 0.29% in 2020, then plummeted by -283bps to 0.53% in 2021, then grew by 15bps to 0.45% in 2022, then tumbled by -41bps to 0.64% in 2023, then skyrocketed by 561bps to 2.94% in 2024.
- Its last three reported values are 2.94% in Q4 2024, 2.26% for Q2 2024, and 0.64% during Q4 2023.